Literature DB >> 17952649

Cannabinoids and multiple sclerosis.

Roger G Pertwee1.   

Abstract

This review discusses clinical and preclinical evidence that supports the use of cannabinoid receptor agonists for the management of multiple sclerosis. In addition, it considers preclinical findings that suggest that as well as ameliorating signs and symptoms of multiple sclerosis, cannabinoid CB(1) and/or CB(2) receptor activation may suppress some of the pathological changes that give rise to these signs and symptoms. Evidence that the endocannabinoid system plays a protective role in multiple sclerosis is also discussed as are potential pharmacological strategies for enhancing such protection in the clinic.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17952649     DOI： 10.1007/s12035-007-0005-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN： 0893-7648            Impact factor:   5.590


  100 in total

1.  Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.

Authors:  Katarzyna Maresz; Erica J Carrier; Eugene D Ponomarev; Cecilia J Hillard; Bonnie N Dittel
Journal:  J Neurochem       Date:  2005-08-08       Impact factor: 5.372

2.  Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.

Authors:  Ana Cabranes; Katerina Venderova; Eva de Lago; Filomena Fezza; Antonio Sánchez; Leyre Mestre; Marta Valenti; Antonio García-Merino; José Antonio Ramos; Vincenzo Di Marzo; Javier Fernández-Ruiz
Journal:  Neurobiol Dis       Date:  2005-11       Impact factor: 5.996

3.  Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats.

Authors:  Grewo Lim; Backil Sung; Ru-Rong Ji; Jianren Mao
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

4.  Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  C Vaney; M Heinzel-Gutenbrunner; P Jobin; F Tschopp; B Gattlen; U Hagen; M Schnelle; M Reif
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

5.  Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.

Authors:  J Ludovic Croxford; Stephen D Miller
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

6.  Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers.

Authors:  H S Greenberg; S A Werness; J E Pugh; R O Andrus; D J Anderson; E F Domino
Journal:  Clin Pharmacol Ther       Date:  1994-03       Impact factor: 6.875

7.  Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Authors:  D Baker; G Pryce; J L Croxford; P Brown; R G Pertwee; J W Huffman; L Layward
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

8.  Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.

Authors:  G Pryce; D Baker
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

9.  Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?

Authors:  J D Wilkinson; B J Whalley; D Baker; G Pryce; A Constanti; S Gibbons; E M Williamson
Journal:  J Pharm Pharmacol       Date:  2003-12       Impact factor: 3.765

10.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Authors:  Gareth Pryce; Zubair Ahmed; Deborah J R Hankey; Samuel J Jackson; J Ludovic Croxford; Jennifer M Pocock; Catherine Ledent; Axel Petzold; Alan J Thompson; Gavin Giovannoni; M Louise Cuzner; David Baker
Journal:  Brain       Date:  2003-07-22       Impact factor: 13.501
View more
  23 in total

1.  Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases.

Authors:  Pál Pacher; Zoltán Ungvári
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-18       Impact factor: 4.733

2.  Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach.

Authors:  Claudia Mugnaini; Stefania Nocerino; Valentina Pedani; Serena Pasquini; Andrea Tafi; Maria De Chiaro; Luca Bellucci; Massimo Valoti; Francesca Guida; Livio Luongo; Stefania Dragoni; Alessia Ligresti; Avraham Rosenberg; Daniele Bolognini; Maria Grazia Cascio; Roger G Pertwee; Ruin Moaddel; Sabatino Maione; Vincenzo Di Marzo; Federico Corelli
Journal:  ChemMedChem       Date:  2012-03-02       Impact factor: 3.466

3.  A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.

Authors:  C G Stott; L White; S Wright; D Wilbraham; G W Guy
Journal:  Eur J Clin Pharmacol       Date:  2012-10-04       Impact factor: 2.953

4.  The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.

Authors:  J M Jamontt; A Molleman; R G Pertwee; M E Parsons
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 5.  CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

6.  Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  J Pharmacol Exp Ther       Date:  2016-05-18       Impact factor: 4.030

Review 7.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 8.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

9.  Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.

Authors:  Qing Liu; Manjunatha Bhat; Wayne D Bowen; Jianguo Cheng
Journal:  J Pharmacol Exp Ther       Date:  2009-09-14       Impact factor: 4.030

Review 10.  Emerging strategies for exploiting cannabinoid receptor agonists as medicines.

Authors:  Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2009-02       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.